- Home
- FORR vs TIL Comparison
FORR vs TIL Comparison
Compare FORR & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- TIL
- Stock Information
- Founded
- FORR 1983
- TIL 2018
- Country
- FORR United States
- TIL United States
- Employees
- FORR N/A
- TIL N/A
- Industry
- FORR Diversified Commercial Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- TIL Health Care
- Exchange
- FORR Nasdaq
- TIL Nasdaq
- Market Cap
- FORR 200.2M
- TIL 177.1M
- IPO Year
- FORR 1996
- TIL 2021
- Fundamental
- Price
- FORR $11.21
- TIL $21.03
- Analyst Decision
- FORR
- TIL Buy
- Analyst Count
- FORR 0
- TIL 6
- Target Price
- FORR N/A
- TIL $120.50
- AVG Volume (30 Days)
- FORR 79.8K
- TIL 150.1K
- Earning Date
- FORR 11-04-2025
- TIL 11-12-2025
- Dividend Yield
- FORR N/A
- TIL N/A
- EPS Growth
- FORR N/A
- TIL N/A
- EPS
- FORR N/A
- TIL N/A
- Revenue
- FORR $412,103,000.00
- TIL N/A
- Revenue This Year
- FORR N/A
- TIL N/A
- Revenue Next Year
- FORR $1.51
- TIL N/A
- P/E Ratio
- FORR N/A
- TIL N/A
- Revenue Growth
- FORR N/A
- TIL N/A
- 52 Week Low
- FORR $8.50
- TIL $10.80
- 52 Week High
- FORR $19.74
- TIL $73.69
- Technical
- Relative Strength Index (RSI)
- FORR 72.67
- TIL 37.54
- Support Level
- FORR $9.76
- TIL $20.11
- Resistance Level
- FORR $10.69
- TIL $25.89
- Average True Range (ATR)
- FORR 0.40
- TIL 2.57
- MACD
- FORR 0.16
- TIL -0.69
- Stochastic Oscillator
- FORR 83.41
- TIL 6.70
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.